Kuopio University Hospital, Diagnostic Imaging Centre, Department of Clinical Radiology, Kuopio University Hospital, PO Box 100, Puijonlaaksontie 2, 70029, Kuopio, Finland.
University of Eastern Finland, Institute of Clinical Medicine, School of Medicine, Department of Clinical Radiology, Kuopio University Hospital, PO Box 1777, Puijonlaaksontie 2, 70210, Kuopio, Finland.
Sci Rep. 2018 Jan 8;8(1):87. doi: 10.1038/s41598-017-18035-0.
To retrospectively evaluated the influence of administration of the gadolinium based intravenous contrast agent (G-CA) on apparent diffusion coefficient (ADC) values in ADC maps generated using multiple b value combinations. A total of 106 women underwent bilateral 3.0 T breast MRI. As an internal validation, diffusion-weighted imaging (b values of 0, 200, 400, 600, 800 s/mm) was performed before and after the G-CA (gadoterate meglumine (0.2 ml/kg, 3 ml/s)). Whole lesion and fibroglandular tissue (FGT) covering region-of-interests (ROIs) were drawn on the b = 800 s/mm images; ROIs were then propagated to multiple retrospectively generated ADC maps. Twenty-seven patients (mean age 55.8 ± 10.8 years) with 32 mass-like enhancing breast lesions including 25 (78.1 %) histopathologically malignant lesions were enrolled. Lesion ADC values were statistically significantly higher in pre-G-CA than post-G-CA ADC maps (ADC: 1.05 ± 0.35 × 10 mm/s vs. 1.02 ± 0.36 × 10 mm/s (P < 0.05); ADC: 1.25 ± 0.42 × 10 mm/s vs. 1.20 ± 0.35 × 10 mm/s (P < 0.05)). ADC values between pre- and post-contrast maps were not statistically different when the maps were generated using other b value combinations. Contrast agent administration did not affect the FGT ADC values. G-CA statistically significantly reduced the ADC values of breast lesions on ADC maps generated using the clinically widely utilized b values.
回顾性评估在使用不同 b 值组合生成 ADC 图时，静脉注射钆基对比剂（G-CA）给药对表观扩散系数（ADC）值的影响。
共 106 名女性接受双侧 3.0T 乳腺 MRI 检查。作为内部验证，在 G-CA（钆特酸葡胺（0.2ml/kg，3ml/s））给药前后进行扩散加权成像（b 值为 0、200、400、600、800s/mm）。在 b=800s/mm 图像上对整个病变和纤维腺体组织（FGT）覆盖 ROI 进行勾画；然后将 ROI 传播到多个回顾性生成的 ADC 图中。
共纳入 27 例（平均年龄 55.8±10.8 岁）、32 个肿块样强化乳腺病变患者，其中 25 例（78.1%）经病理证实为恶性病变。与 G-CA 后 ADC 图相比，G-CA 前 ADC 图的病变 ADC 值明显升高（ADC：1.05±0.35×10mm/s 比 1.02±0.36×10mm/s（P<0.05）；ADC：1.25±0.42×10mm/s 比 1.20±0.35×10mm/s（P<0.05））。当使用其他 b 值组合生成 ADC 图时，前后对比图的 ADC 值无统计学差异。对比剂给药未影响 FGT 的 ADC 值。G-CA 给药后，使用临床广泛应用的 b 值生成的 ADC 图中，乳腺病变的 ADC 值明显降低。
G-CA 给药后，使用临床广泛应用的 b 值生成的 ADC 图中，乳腺病变的 ADC 值明显降低。
